Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults.
NBI-1076986-1761
Phase 1 other active
Quick answer
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults. for Movement disorders is a Phase 1 program (other) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Movement disorders
- Phase
- Phase 1
- Modality
- other
- Status
- active